A New Treatment Landscape for RCC: Association of the Human Microbiome with Improved Outcomes in RCC.

ABSTRACT: Microbes play different roles in metabolism, local or systemic inflammation, and immunity, and the human microbiome in tumor microenvironment (TME) is important for modulating the response to immunotherapy in cancer patients. Renal cell carcinoma (RCC) is an immunogenic tumor, and immunotherapy is the backbone of its treatment. Correlations between the microbiome and responsiveness to immune checkpoint inhibitors have been reported. This review summarizes the recent therapeutic strategies for RCC and the effects of TME on the systemic therapy of RCC. The current understanding and advances in microbiome research and the relationship between the microbiome and the response to immunotherapy for RCC are also discussed. Improving our understanding of the role of the microbiome in RCC treatment

SUBMITTER: Piao XM 

PROVIDER: S-EPMC9913391 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature